Lesson
Use time to investigate an acquisition anomaly
Investigate a transient event-rate change without automatically deleting inconvenient events or mistaking event order for measured time.
Open learning item →CFCM Academy / Curriculum edition
A structured learning framework for clinical flow cytometry, from instrument physics and laboratory quality to disease-specific analysis.
Start a released lessonExplore the curriculumLessons, cases and resources appear only after their stated editorial checks are complete. Independent scientific review is identified separately when it has actually occurred.
Find a topic by keyword, module or disease and open its curriculum outline.
Search the curriculumExplore module outlines and learning pathways, then work through the first seven editorially approved lessons below. Each lesson includes a worked example, questions and source references. More lessons and cases are in development.
Our publishing sequence is simple: learn → verify → synthesise → publish. Each teaching item needs traceable sources and accountable editorial review before release. Independent scientific review will be identified only where it has actually occurred.
A minimum educational layer around released guides, clinical reasoning and primary evidence. Use a module to decide what to study next; the full curriculum remains available below.
CFCM Academy / Guided learning
A measurement-based approach to interpreting light scatter and fluorescence. Start with what was acquired, the controls and the biological question before naming a population.
A reproducible label requires reproducible measurement. A false rare population can arise from sample quality or acquisition rather than disease.
Review acquisition stability, singlets, viability where measured and internal comparators. Back-gate a proposed population across independent views. Use Shapiro for the technical framework and the practical guide for worked reasoning.
Treating scatter as a diagnosis, excluding unusual events too early, or confusing compensating a mean spillover with removing spreading.
CFCM Academy / Guided learning
Translate a clinical question into identity, discriminating markers, internal controls and a preparation that preserves the required signals.
Adding markers cannot compensate for a missing lineage question or an unreadable weak discriminator.
Define the differential, select informative combinations, allocate fluorochromes with spreading in mind, titrate and assess the complete stained sample. Use the poster marker briefs as design inputs requiring local verification.
Copying a tube across instruments, assuming every extra colour improves sensitivity, or extending a published validation to a therapy group it excluded.
CFCM Academy / Guided learning
A diagnostic sequence for investigating a measurement problem while keeping competing explanations visible.
An apparent abnormal phenotype can be caused by autofluorescence, Fc binding, poor viability, spreading or an unstable acquisition.
State the observation, compare unstained and single-stained controls where appropriate, distinguish displacement from broadening, test a specific hypothesis and verify the correction.
Increasing antibody without titration, redrawing gates to hide a problem, or treating an isotype control as a universal solution.
CFCM Academy / Guided learning
Disease-centred interpretation connecting phenotype with morphology, tissue context and relevant genetic evidence.
The same surface pattern can support several diagnoses. A characteristic result in one compartment may conflict with a decisive finding elsewhere.
Identify the abnormal compartment, establish relevant lineage or clonality, construct the differential and resolve discordance. Study the CLL exercise, published lymphoma case, AML follow-up and plasma-cell illustration.
Assigning a disease from one marker, a score or a narrow gate; treating a diagnostic panel as a validated MRD method.
CFCM Academy / Guided learning
A disease- and assay-specific assessment separating cell identity, detection and quantification at low abundance.
A credible detected population may still be below reliable quantification. A negative specimen may not support the requested sensitivity.
Use the validated disease-specific strategy, assess specimen adequacy and informative events, corroborate abnormal identity and apply the actual detection and quantification limits.
Transferring a published 20 / 50-event example to another method; reporting a precise percentage at or below the adopted quantification boundary; overlooking treatment interference.
CFCM Academy / Guided learning
Document whether the complete method performs adequately for its intended clinical use, and whether an adopted method works in the local setting.
An apparently clean plot does not establish sensitivity, quantitative precision, specificity or transferability.
Define intended use and acceptance criteria first. Assess controls, background, low-level precision, recovery, stability and relevant interferences. Evaluate the impact of changes to clones, preparation, panel or instrument.
Treating a literature claim as local validation, using only abundant positives, or ignoring specimen limitations when stating the achieved sensitivity.
These modules organise existing CFCM material rather than duplicate full protocols. Primary sources and figure rights are stated in each guide, case and poster. No accreditation, validated universal panel or independent clinical review is implied.
Shapiro · Practical Flow Cytometry · 4th edition · DOI 10.1002/0471722731
Wood et al. · ICSH / ICCS assay performance criteria · DOI 10.1002/cyto.b.21108
Start with the foundations or enter through a practical question. MRD is studied within each relevant disease pathway.
Explore the instrument from sample stream to measured signal, with a learning sequence covering light, fluorescence and measurement quality.
Explore the curriculum →Module 02Follow the laboratory workflow through quality control, documentation and traceability. Topics distinguish general quality practice from requirements that depend on the laboratory's intended activities.
Explore the curriculum →Module 03Build a structured approach to selecting markers and fluorochromes, then review controls and the evidence needed to assess a panel.
Explore the curriculum →Module 04Connect instrument setup with panel optimisation and long-term monitoring. The curriculum separates transferable principles from instrument-specific instructions.
Explore the curriculum →Module 05Work through problems by identifying the affected stage, checking evidence and documenting the investigation before changing a workflow.
Explore the curriculum →Module 06Organise a study around intended use, performance claims and the questions that its data must answer. The topics connect study design, analysis and reporting.
Explore the curriculum →Module 07Learn through disease-centred pathways that connect diagnostic interpretation, follow-up and case discussion. MRD is studied within the relevant disease pathway.
Explore the curriculum →Within data analysis
Diagnostic interpretation, follow-up and MRD are organised in their clinical context.
A disease-centred learning pathway for B-cell Acute Lymphoblastic Leukaemia (B-ALL). Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Disease pathwayA disease-centred learning pathway for T-cell Acute Lymphoblastic Leukaemia (T-ALL). Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Disease pathwayA disease-centred learning pathway for Acute Myeloid Leukaemia (AML). Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Disease pathwayA disease-centred learning pathway for Chronic Lymphocytic Leukaemia (CLL). Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Disease pathwayA disease-centred learning pathway for B-cell lymphoproliferative disorders (B-LPD). Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Disease pathwayA disease-centred learning pathway for Plasma cell neoplasms. Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Disease pathwayA disease-centred learning pathway for Myelodysplastic neoplasms / MDS. Explore diagnostic interpretation, follow-up, reporting and case discussion within the same clinical context.
Explore the curriculum →Suggested learning sequences connect the curriculum. The first seven lessons are available below; progress tracking is not active.
Start with instrument principles, laboratory quality and basic panel design.
Explore the curriculum →Learning pathFollow marker and fluorochrome selection through controls, setup and panel assessment.
Explore the curriculum →Learning pathWork from intended use and performance claims to study design, analysis and reporting.
Explore the curriculum →Learning pathStudy MRD within the appropriate disease pathway, with links to detection, quantification and reporting.
Explore the curriculum →Start with the clinical question, then compare the observations, differential diagnoses and limits of the evidence.
Five clinical reasoning explanations are available in Clinical Cases, using published material or explicitly labelled educational exercises.
Read existing Clinical Notes →Build the concepts, then connect them to practical laboratory decisions.
Examine complex interpretation, validation decisions and uncertainty.
Search the curriculum or choose one of the released lessons. Lesson-level filters and progress tracking are not available.